Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S569000, C548S570000
Reexamination Certificate
active
06878736
ABSTRACT:
Compounds of formula (I) (and pharmaceutically acceptable salts thereof) are histamine H3receptor ligands. A in the formula represents (CH2)m, m being from 1 to 3; B is (CH2)n, n being from 1 to 3; x is from 0 to 2; R1is C1to C10hydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N; and up to 2 hydrogen atoms may be replaced by halogen; R2is H or C1to C15hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen; R3is absent when —Y—Z—R2is attached to W, or is H or C1to C7hydrocarbyl when —Y—Z—R2is not attached to W; W is nitrogen; X is —CH2—, —O— or —NR4—, R4being H or C1to C3alkyl; Y replaces a hydrogen atom on any of A, B, W and X, and is C2to C10alkylene, in which one non-terminal carbon atom may be replaced by O; and Z is (II), (III), (IV), (V), (VI), or (VII) wherein R5, R6and R7are independently H or C1to C15hydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to R5or R7to form a five-membered ring or Q is linked to R2to form a six-membered ring
REFERENCES:
patent: 4132786 (1979-01-01), Moreau et al.
patent: 4372955 (1983-02-01), Jozic
patent: 4396622 (1983-08-01), Jozic
patent: 5281625 (1994-01-01), Zipplies et al.
patent: 5453437 (1995-09-01), Schohe et al.
patent: 342 957 (1959-12-01), None
patent: 345 893 (1960-04-01), None
patent: 346 879 (1960-06-01), None
patent: 362 079 (1962-05-01), None
patent: 390 925 (1965-04-01), None
patent: 390 926 (1965-04-01), None
patent: 390 927 (1965-04-01), None
patent: 390 928 (1965-04-01), None
patent: 393 337 (1965-06-01), None
patent: 442 298 (1967-08-01), None
patent: 0 199 845 (1986-11-01), None
patent: 0 525 203 (1993-02-01), None
patent: 1352161 (1964-05-01), None
patent: 2694003 (1994-01-01), None
patent: 952194 (1961-12-01), None
patent: 1185080 (1970-03-01), None
patent: 42-21010 (1967-10-01), None
patent: 9215567 (1992-09-01), None
patent: 9314070 (1993-07-01), None
patent: 9729092 (1997-08-01), None
patent: 9745108 (1997-12-01), None
Unterhalt et al. (Archiv der Pharmazie (Weinheim, Germany) (1982), 315(10), 852-7). Unterhalt et al. (Archiv der Pharmazie (Weinheim, Germany) (1982), 315(10), 852-7).*
Moreau et al. (Annales Pharmaceutiques Francaises (1981), 39(3), 283-90).*
Zikolova et al. (Farmatsiya (Sofia) (1962); 17(6), 6-10).*
Dahlbom et al. (Acta Phar. Suecica (1968), 5(2), 95-100).*
Boudet-Dalbin et al. (Eur. J. Med. Chem. —Chim. Ther. (1986), 21(2), 131-7). Abstract.*
Schoha et al. (US 5,274,097) 1993. Abstract.*
Sato et al. (WO 93/04042). 1993. Abstract.*
Vorbrueggen et al. (Chemische Berichte (1984), 117(4), 1523-41.*
Ganellin et al., “Synthesis of Potent Non-imidazole Histamine H3-Receptor Antagonists”, Arch. Pharm. Pharm. Med. Chem., 331:389-394, (1998), Wiley-VCH Verlag GmbH.
Decicco et al., “Amide Surrogates of Matrix Metlloproteinase inhibitors: urea and sulfonamide mimics”, Bioorganic Medicinal Chemistry Letters, vol. 7, No. 8, pp. 2331-2336, 1997, The DuPont Merck Pharm. Co.
MacPherson et al., “Discovery of CGS 27023A, a Non-Peptide, potent, and orally active stromelysin inhibitor That blocks cartilage degradation in rabbits”, J. Med. Chem., 40:2525-2532, 1997, American Chemical Society.
Wolin et al., “Novel H3receptor antagonists. Sulfonamide homologs of histamine”, Bioorganic & Medicinal Chemistry letters 8 (1998) pp. 2157-2162, Elsevier Science Ltd.
Vollinga et al., “Homologs of Histamine as histamine H3receptor anatagonists: a new potent and selective H3Antagonist, 4(5)-(5-Aminopentyl)-1H-imidazole”, J. Med. Dhem. 1995, 38:266-271, American Chem. Soc.
Timmerman, “Histamine H3ligands: just pharmacological tools or potential therapeutic agents?”, J. Med. Chem., 1990, 33:4-11, American Chemical Society.
Stürzebecher et al., “Synthesis and structure-activity relationship of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine”, J. Med. Chem., 1997, 40:3091-3099, Pentapharm Ltd.
Young et al., “Development of a new physicochemical model for brain penetration and its application to the Design of centrally acting H2receptor histamine antagonist”, J. Med. Chem. 1988, 31:656-671, Smith Kline & French Research Ltd.
Vollinga, “New ligands of the histamine H3receptor”, Synthesis, Structure activity relationships and molecular Pharmacology, pp: 7-210, 1995, Leiden/Amsterdam center for drug research.
Buck Ildiko Maria
Harper Elaine Anne
Kalindjian Sarkis Barret
Linney Ian Duncan
Shankley Nigel Paul
Foley & Lardner LLP
James Black Foundation Limited
Kifle Bruck
LandOfFree
Histamine H3 receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histamine H3 receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histamine H3 receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374757